Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

MedicalMinute: Updates on Emerging Oral Therapies for IBD
  • CME
  • CE

Credits Available
Physicians: maximum of 0.25 AMA PRA Category 1 Credits
Registered Nurses: 0.25 Nursing contact hours
Released: August 24, 2021 Expiration: August 23, 2022
Start Activity
Provided by Clinical Care Options

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AbbVie
Bristol-Myers Squibb
Millie D. Long, MD, MPH

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Summarize late-phase trial results for emerging oral IBD therapies such as JAK inhibitors and S1P receptor modulators

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty

Millie D. Long, MD, MPH

Associate Professor of Medicine
Director,
Gastroenterology and Hepatology Fellowship Program
Vice-Chief for Education
Division of Gastroenterology and Hepatology 
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina

Millie D. Long, MD, MPH, has disclosed that she has received consulting fees from AbbVie, Bristol-Myers Squibb, Genentech, Janssen, Lilly, Pfizer, Prometheus, Roche, Salix, Takeda, Target, and Theravance and funds for research support from Pfizer and Takeda.

Staff

Craig Borders
Vice President, Managing Scientific Director
Craig Borders has no relevant conflicts of interest to report.
Kiran D. Mir-Hudgeons, PhD

Manager, Editorial Operations

Kiran Mir-Hudgeons, PhD, has no relevant conflicts of interest to report.
Ruth Cohen Cooper, CHCP

Vice President, Science and Strategy

Ruth Cohen Cooper, CHCP, has no relevant conflicts of interest to report.
Carolyn Skowronski, PharmD

Associate Director, Scientific Services

Carolyn Skowronski, PharmD, has no relevant conflicts of interest to report.
Beth-Ann Norton, MS, RN, ANP-BC
Beth-Ann Norton, MS, RN, ANP-BC, has disclosed that she has received consulting fees from AbbVie, Bristol-Myers Squibb, and Pfizer.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for gastroenterologists, advanced practice clinicians, nurses, and other healthcare providers who care for patients with IBD.

Goal

The goal of this activity is to improve learners’ competence in navigating the most challenging clinical issues related to IBD care so that both patient and clinician are satisfied with treatment outcomes.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.25 contact hours.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from August 24, 2021, through August 23, 2022:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 100% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

MedicalMinute: Updates on Emerging Oral Therapies for IBD
  • CME
  • CE

Loading...
Expert review of safety and efficacy data on new and emerging oral therapies for IBD, including S1PR modulators and JAK-STAT inhibitors.
Millie D. Long, MD, MPH
Physicians: maximum of 0.25 AMA PRA Category 1 Credits
Registered Nurses: 0.25 Nursing contact hours
Released: August 24, 2021 Expiration: August 23, 2022

Related Content

Downloadable slides covering safety and efficacy data on new and emerging oral therapies for IBD, including S1PR modulators and JAK-STAT inhibitors.

Millie D. Long, MD, MPH Released: August 24, 2021

Expert commentary from Dr. Millie Long on the benefits of and barriers to patient participation in IBD clinical trials, from Clinical Care Options (CCO)

Millie D. Long, MD, MPH Released: August 17, 2021

Expert commentary from Dr. Millie Long on developing “activated” patients with IBD in your practice, from Clinical Care Options (CCO)

Millie D. Long, MD, MPH Released: July 13, 2021

Downloadable slides covering best practices of shared-decision making and discussing cancer risk when discussing initiation of biologic therapy with patients who have IBD

Millie D. Long, MD, MPH Released: June 24, 2021
Provided by Clinical Care Options

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AbbVie
Bristol-Myers Squibb

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue